Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0596263 (
carcinogenesis
)
64,820
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ribosomal protein L22
(
RPL22
), an RNA-binding protein, is a constituent of the 60S large ribosomal subunit. As reported,
RPL22
is not required in protein synthesis, and mutations of
RPL22
were the main cause of macrolide resistance in bacteria. In vertebrates,
RPL22
mutation might increase the proliferation of cells and then increase cancer risk. However, to our knowledge,
RPL22
has not been implicated in any lung diseases, especially in lung cancer. In this study, we compared the expression of
RPL22
gene in non-small cell lung cancer (NSCLC) tissues, plasma as well as human lung cancer cell line LTEP-a-2 with that in normal lung tissues and cells, using real-time RT-qPCR, Western blot, quantitative immunohistochemistry analysis, and ELISA. Our studies showed that the expression of
RPL22
was significantly down-regulated in mRNA and protein expression level in NSCLC; however, there was no significant difference of
RPL22
levels in plasma between normal and NSCLC patients. Further analysis indicated that down-regulation of
RPL22
might be involved in the
carcinogenesis
of NSCLC, yet not an effective biomarker in plasma for early diagnosis.
...
PMID:Down-regulation of ribosomal protein L22 in non-small cell lung cancer. 2379 73
